Backgound and objective: Although the PROWESS trial demonstrated a mortality benefit, subsequent studies in different patient populations have not reproduced the effect. As a result, concerns have been expressed about the clinical effectiveness of drotrecogin alfa (activated). Therefore the aim of this audit was to review the clinical impact of drotrecogin alfa (activated) when used outside clinical trials. Methods: A retrospective review of ICU charts and medical records of patients who had received drotrecogin alfa (activated) in the five largest users of drotrecogin alfa (activated) in England. Patients characteristics details at ICU admission and vital status at hospital discharge were recorded. The severity of illness was assessed by the APACHE II score (using first 24 h admission data) and the number of organ dysfunctions. Adverse incidents were recorded and any sequence effect explored. Results: In all, 351 patients received drotrecogin alfa (activated) between December 2002 and November 2005. Of those, 201 (57.2%) were male, and 177 (50.4%) were admitted after recent surgery. The patients' average age was 61.8 yr. The mean admission APACHE II score was 23.3 and the average number of dysfunctional organs on admission was 3.3. The hospital mortality was 46.7% (164 deaths). The expected number of deaths calculated by using the APACHE II risk of death was 173 (49.3%) and by number of sepsis induced organ failures 210 (59.7%). Overall, there were 33 (9.4%) adverse incidents. Conclusions: Expected mortality derived from both the APACHE II score and organ dysfunctions suggests that drotrecogin alfa (activated) does reduce mortality. Serious adverse incidents occurred in 5.1% patients; however, the direct contributing effect of drotrecogin alfa (activated) cannot be established from this type of audit.
Introduction
In 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial of 1690 patients were published and demonstrated that a 96 h intravenous infusion of drotrecogin alfa (activated) (Xigris s ; Lilly UK, Basingstoke, Hampshire, UK) (24 mg kg 21 h 21 ) reduced all-cause mortality significantly compared to placebo at 28 days [1] . All-cause day 28 mortality was 24.7% for patients treated with the drug compared to 30.8% among controls (P , 0.005), yielding a number needed to treat of 16 to avoid one death. European regulatory approval was granted in 2002, and in the UK, drotrecogin alfa (activated) was recommended by the National Institute for Clinical Excellence (NICE) for use in patients with severe sepsis and multiple organ failure in 2004 [2] . The phase IIIb ENHANCE trial [3] appeared to confirm the safety and efficacy of the drug.
Some concerns were raised, however, following the results from the later ADDRESS trial [4] . This trial confirmed that single organ failure patients are unlikely to benefit from drotrecogin alfa (activated). Even so together with concerns about possible adverse effects, there were calls from some quarters for a formal reappraisal of the drug's role [5] . Others more rationally suggested that there should be greater emphasis placed on identifying those highrisk patients most likely to benefit [6] .
Further examination of the original PROWESS trial data [7] revealed a possible site sequence effect where the beneficial effect of drotrecogin alfa (activated) was greater in sites enrolling larger numbers of patients. A similar effect might occur in routine clinical practice where intensivists become more familiar with the indications and optimal timing for the drug's administration.
Therefore we reviewed the clinical efficacy of drotrecogin alfa (activated) by measuring the hospital mortality of patients with severe sepsis in the five largest users of drotrecogin alfa (activated) in England.
Methods
The five largest users of drotrecogin alfa (activated) were identified from sale figures provided by the drug manufacturer (Lilly UK, personal communication). The study was registered with the appropriate authority (either Clinical Ethics Committee or Research and Development Department) in each of the hospitals involved. In three of the five hospitals (Guy's & St Thomas', Addenbrookes and Southend Hospitals), the study involved a retrospective review of prospectively collected data whereas in the remaining two hospitals (University Hospitals Coventry & Warwickshire and Norfolk & Norwich University Hospital) a retrospective notes review was undertaken. All patients who had sepsis as part of their presenting condition to ICU and subsequently received drotrecogin alfa (activated) outside a clinical trial were enrolled; these patients were identified by ICU and pharmacy records. Although the precise prescription criteria were not identical in all five hospitals, patients received the drug according to local protocols, which were based upon the European Summary of Product Characteristics (i.e. severe sepsis with two or more organ dysfunctions). Organ dysfunction was defined using similar criteria to the PROWESS trial (Appendix A).
The patients characteristics details (age, sex and whether they had undergone recent surgery) and vital status at hospital discharge were recorded. Unlike the PROWESS and ENHANCE trials, the severity of illness was assessed by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score using first 24 h admission data [8] . The primary source of sepsis was also recorded. These patients were compared to data published in an Intensive Care National Audit & Research Centre (ICNARC) study [9] of 15 362 critically ill patients admitted with severe sepsis to selected UK ICUs between 1995 and 2000. The ICNARC report also stratified the mortality of critically ill patients by number of sepsis induced organ failures (one organ dysfunction 21.8%, two organ dysfunctions 36.0%, three organ dysfunctions 52.5%, four organ dysfunctions 75.1% and five organ dysfunctions 86.1%).
As anti-coagulation is a pharmacodynamic effect of drotrecogin alfa (activated), all adverse incidents, especially bleeding, were recorded. To test for a site sequence effect, the order in which the patients presented to ICU was recorded and the cumulative hospital mortality calculated with increasing numbers of patients treated.
Because of the retrospective observational nature of this review, statistical analysis was limited to exploring differences in distributions using x 2 tests and the general linear model for univariate analysis of variance in unbalanced designs. A P value of ,0.05 was considered significant. Minitab Statistical Sotfware version 13 (Minitab Inc., State College, PA, USA) was used for the analysis.
Results
In the five hospitals, a total 351 patients received drotrecogin alfa (activated) between December 2002 and November 2005 (Table 1) ; all the relevant data were retrieved. Comparable data from the ICNARC study are also shown in the table. In the entire group, 201 (57.2%) were male, and 177 (50.4%) were admitted after recent surgery. The average (SD) age was 61.8 (16.3) yr. The median (interquartile range, IQR) length of stay on ICU was 12 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) days while the median (IQR) total hospital stay was 27 (13-51) days. The sites of sepsis were lung (usually pneumonia with septic shock) 46.7% (n 5 164), abdomen (including peritonitis, perforation with shock) 35.6% (n 5 125), other (including blood, skin, central nervous system, cardiac system, bone and joint and reproductive system) 13.6% (n 5 48) and urosepsis 4% (n 5 14). Intra-abdominal and respiratory causes were the most common (82.3% of total). The mean admission APACHE II score was 23.2 (SD 7.2). The distribution of APACHE scores for all patients (and critically ill patients reported in ICNARC study) is shown in Figure 1 . The average number of dysfunctional organs on admission was 3.3 (SD 1.0); Figure 2 gives the distribution of number of dysfunctional organs together with the associated mortality.
The overall hospital mortality was 46.7% (164 deaths). The expected number of deaths can be calculated by using the APACHE II score. This calculation involves transformation of the score into a risk of hospital mortality using a coefficient for a specific diagnosis and, if appropriate, a coefficient for admission following emergency surgery. When the diagnostic coefficient for the diagnosis that prompted ICU admission (e.g. pneumonia) was used, the expected number of deaths was 173 (49.3%) (x 2 0.462, degrees of freedom (df) 5 1, P 5 0.50). If the raw APACHE score was transformed using the coefficient for sepsis, the expected number of deaths was 189 (54.0%) (x 2 3.561, df 5 1, P 5 0.059). Using the mortality rates reported in the ICNARC study, the expected number of deaths was 210 (59.7%) (x 2 12.1, df 5 1, P 5 0.001).
Overall, there were 33 (9.4%) adverse incidents. Of these, there were eight serious bleeds (two intracranial bleeds, two haemothoraces, three gastrointestinal and one episode of bleeding from multiple sites), 10 less serious gastrointestinal haemorrhages, and 15 more minor incidents. No adverse incidents were directly associated with patient mortality.
The average cumulative mortality of the patients enrolled at the five hospitals started at between 35% and 40% before becoming more constant at 45-48% after about 50 patients. If the patients are divided into blocks of 10, there is no significant difference between the first and subsequent blocks with regard to the patients' ages, number of organs failing and risks of hospital mortality using the individual diagnostic codes. However, there was a significant difference between the APACHE scores in the blocks of patients (P 5 0.049). In the first 10 patients, the average APACHE score was 24; this decreased to 22.7 and 23.9 in the second and third blocks, respectively, before increasing to 26.8 and 25.3 in the fourth and fifth blocks, respectively. The data from the ICNARC study [9] is also shown. * Median (IQR). 
Discussion
Padkin and colleagues [9] previously published a report of the epidemiology of severe sepsis occurring in the first 24 h in ICUs in England, Wales and Northern Ireland before the introduction of drotrecogin alfa (activated) into clinical practice. This ICNARC study was based upon 15 362 patients treated between 1995 and 2000. The main result was that the hospital mortality of these patients was 47.3%; our results are similar (46.7%). Most of our patients characteristics details are very similar to those in the ICNARC study; they were of similar age (65 (53-74) yr vs. 65 (51-73) yr in the ICNARC study) and similar sex distribution (maleto-female ratio 1 : 0.84 vs. 1 : 0.75 in the ICNARC study). However, there are some differences; our review contained a greater proportion of patients who had undergone recent surgery (50.4% vs. 33.0% in the ICNARC study); the effect of this difference is difficult to predict. Most importantly, in ICNARC's cohort 65.2% of patients had two or more organs failing while in our study, 350 out of 351 patients (99.7%) had two or more organs failing (so complying with the manufacturer's recommendations in all but one patient). The distribution of APACHE scores also appears greater in our patients (Fig. 1) ; 52.3% of our patients had an APACHE score greater than 23 vs. 32.7% in the ICNARC study. The greater organ dysfunction and severity of illness in our patients were also associated with longer stays in ICU (median (IQR) 12 (6-22) days vs. median (IQR) 3.59 (1.5-9.33) days in the ICNARC study) and total hospital stay (median (IQR) 27 (13-51) days vs. median (IQR) 18 (8-36) days in the ICNARC study). With greater severity of illness and organ dysfunction associated with longer stays in hospital, higher hospital mortality than that in the ICNARC study could be expected. Our study aimed to review the use of drotrecogin alfa (activated) in the five largest users of the agent in England. Of the hospitals concerned, two were large teaching centres with tertiary referral specialties, two were university affiliated hospitals and one a district general hospital. The characteristics data of the patients enrolled in the study are likely to be different (as suggested in Table 1 ). However, the purpose of the study was not to match patients as in a clinical trial but to report what happens when drotrecogin alfa (activated) is used in everyday clinical practice.
One of the interesting results of our audit is the nearly 13% higher mortality reported in our 81 patients with two organ failures compared to the ICNARC paper (48.8% vs. 36.0%). The reasons for this higher mortality are not clear but, overall, our results support the recognized greater effect of drotrecogin alfa (activated) in the sicker patients.
Calculating the expected mortality in an observational study of clinical practice such as ours is difficult. If expected mortality is assessed using the APACHE II score, then the risk reduction is not significant. Using a diagnostic coefficient for the specific pathology precipitating ICU admission rather than sepsis generates an expected mortality of 49.3% while using the sepsis coefficient yields a slightly higher mortality at 54.0%. If these expected mortalities are accurate, then an absolute risk reduction of between 2.6% and 7.3% is being achieved. However, there may be several reasons why an expected mortality based upon the APACHE II score may underestimate the risk of hospital mortality in this patient population. First, although the acute physiology score will accurately quantify physiological disturbance, the diagnostic coefficient applied for risk of hospital death calculation is a generic value applied to the entire range of illness within a diagnostic group. For example, the same coefficient value is used whether the patient has only pneumonia or pneumonia associated with septic shock, the latter having a much more serious prognosis that may not be adequately adjusted by the acute physiology score. Second, although the expected mortality increased when the coefficient for sepsis was used, this still may not be appropriate because in nearly all of the patients in our cohort, sepsis was associated with at least two organ failures. The coefficients for transformation of the APACHE score based on disturbance of more than one vital organ system have not been published. Because of the well-recognized association between increasing organ dysfunction and increasing hospital mortality [10] , such coefficients, if they existed, might be expected to generate higher risk of death. Therefore we would suggest that the 2.6-7.3% risk reduction is likely to be a conservative estimate. It is important to stress that even at an absolute risk reduction of only 2.6%, the cost effectiveness of drotrecogin alfa (activated) remains below £30 000 per quality-adjusted life year (QALY), the threshold set by NICE [11] .
Calculating the expected mortality using the number of dysfunctional organs may be more appropriate, especially as the reference data in the ICNARC study [9] is more recent, being published shortly before the introduction of drotrecogin alfa (activated) into clinical practice and most importantly being based upon a large cohort of English patients. Using the expected mortality generated by organ dysfunction (59.7%), the absolute risk reduction is 13%. This mirrors clinical experience elsewhere in Europe. The Polish Society of Anesthesiology and Intensive Care have reported the ICU mortality of 3233 patients with severe sepsis. In the 302 patients with an average of 3.7 organ dysfunctions who have received drotrecogin alfa (activated), the ICU mortality was 38.9%. The ICU mortality of the other similar patients was 56.2% representing an absolute risk reduction of 17.3% [12] . The Belgium Registry of patients who have received drotrecogin alfa (activated) suggests that patients with two or more organ dysfunctions had an actual hospital mortality of 50.7% when their expected mortality was 63.3% (absolute risk reduction 12.8%) [13] . Therefore, allowing for inter-country variations in case-mix and practice, an absolute risk reduction of 13% would seem a reasonable estimate of the clinical impact of drotrecogin alfa (activated) in England.
Prescription of drotrecogin alfa (activated) in the presence of two or more organ failures was recommended by NICE after rejecting using an APACHE score threshold value. If, as the Food and Drug Administration (FDA) has recommended, drotrecogin alfa (activated) is given when the APACHE II score reaches 25, then 210 patients with an average of 3.2 organ dysfunctions would have not received the drug. Their expected mortality would have been 35.7% calculated by APACHE score or 57.4% by organ dysfunction as opposed to an actual mortality of 37.6%. Our review suggests that in the UK, at least, prescription based upon number of organ dysfunctions is the correct approach as it offers the benefit of the drug to the largest number of patients with severe sepsis.
There seems to be a learning curve with the use of drotrecogin alfa (activated). It appears that initially intensivists at the five hospitals restricted the use of the drug to patients who, in their opinion had a good chance of hospital survival. This was reflected with a lower mortality with early use. As intensivists became more familiar and confident with use of the drug, prescription may have become more routine and protocolized. As a result, patients with an intrinsically poorer prognosis may have received the drug. This may explain the higher APACHE score in the blocks of over 40 patients.
In conclusion, in a group of 351 septic patients with greater severity of illness and more organ dysfunction than a previously published report, hospital mortality was similar. Assessing the risk of death using either the APACHE score or number of organ failure, the absolute risk reduction achieved by drotrecogin alfa (activated) varies between 2.6% and 13%. Serious adverse incidents occurred in 5.1% of patients; however, the direct contributing effect of drotrecogin alfa (activated) cannot be established from this type of audit. 
